ICLR vs. JNJ: ICON vs. Johnson & Johnson Stock Comparison
How do ICON (ICLR) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
ICON (ICLR) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while JNJ is classified in Pharmaceuticals.
| Profile Item | ICLR | JNJ |
|---|---|---|
| Name | ICON plc | Johnson & Johnson |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 15.34 billion USD | 664.95 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | May 15, 1998 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ICLR | JNJ |
|---|---|---|
| Total Return (1Y) | 30.55% | 53.82% |
| Total Return (3Y, Annualized) | -6.05% | 27.51% |
| Total Return (5Y, Annualized) | -5.40% | 14.71% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ICLR | JNJ |
|---|---|---|
| Volatility (1Y, Annualized) | 68.62% | 21.23% |
| Beta (5Y) | 1.17 | 0.21 |
| Max Drawdown (5Y) | -76.87% | -18.41% |
| Avg. Volume (3M) | 943.50K | 6.93M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ICLR | JNJ |
|---|---|---|
| Sharpe Ratio (1Y) | 0.38 | 2.33 |
| Sortino Ratio (1Y) | 0.52 | 3.66 |
Profitability
ROE (TTM)
Johnson & Johnson (JNJ) at 20.02% sits in the top ROE quartile, while ICON (ICLR) at 4.70% is closer to the peer norm — stronger capital efficiency for JNJ.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70%
- Max
- 109.18%
- Q3
- 6.23%
- ICLR
- 4.70%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.02%
- Max
- 109.18%
- JNJ
- 20.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both ICON (ICLR) at 5.26% and Johnson & Johnson (JNJ) at 16.20% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.26%
- Max
- 18.05%
- ICLR
- 5.26%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.20%
- Max
- 18.05%
- JNJ
- 16.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Johnson & Johnson (JNJ) at 25.74% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.73%
- Max
- 83.12%
- Q3
- 14.77%
- ICLR
- 10.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.74%
- Max
- 83.12%
- JNJ
- 25.74%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ICLR | JNJ |
|---|---|---|
| ROE (TTM) | 4.70% | 20.02% |
| ROA (TTM) | 0.85% | 8.46% |
| Net Margin (TTM) | 5.26% | 16.20% |
| Operating Margin (TTM) | 10.73% | 25.74% |
| Gross Margin (TTM) | 23.44% | 67.78% |
Growth
Revenue Growth
Both ICON (ICLR) at 0.76% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while ICON (ICLR) at -71.56% is in the bottom quartile, showing a clear gap in earnings momentum.
Growth Metrics
| Metric | ICLR | JNJ |
|---|---|---|
| Revenue Growth (YoY) | 0.76% | 6.05% |
| Revenue Growth (3Y CAGR) | 2.15% | 5.60% |
| EPS Growth (YoY) | -71.56% | 90.50% |
| EPS Growth (3Y CAGR) | -23.82% | 17.90% |
Financial Strength
Current Ratio (MRQ)
Both ICON (ICLR) at 1.32 and Johnson & Johnson (JNJ) at 1.02 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.32
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ICLR
- 1.32
- Min
- 0.10
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.02
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JNJ
- 1.02
- Min
- 0.10
Debt / Equity (MRQ)
Both ICON (ICLR) at 0.38 and Johnson & Johnson (JNJ) at 0.55 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- ICLR
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.55
- Max
- 1.42
- Q3
- 0.65
- JNJ
- 0.55
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ICLR | JNJ |
|---|---|---|
| Current Ratio (MRQ) | 1.32 | 1.02 |
| Debt / Equity (MRQ) | 0.38 | 0.55 |
| Net Debt / EBITDA | 5.55 | 0.79 |
Dividends
Dividend Yield (TTM)
ICON (ICLR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94%
- JNJ
- 1.94%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
ICON (ICLR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
80.12%
- JNJ
- 80.12%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ICLR | JNJ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.94% |
| Dividend Payout Ratio (TTM) | 0.00% | 80.12% |
Valuation
P/E Ratio (TTM)
Johnson & Johnson (JNJ) at 41.92 is near its industry’s usual P/E ratio, while ICON (ICLR) at 81.90 sits in the richer quartile — ICLR needs stronger growth or earnings quality to justify the premium.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.90
- Max
- 85.34
- ICLR
- 81.90
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.92
- Max
- 85.34
- Q3
- 43.46
- JNJ
- 41.92
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Johnson & Johnson (JNJ) at 6.69 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.86
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ICLR
- 1.86
- Min
- 0.01
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JNJ
- 6.69
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
ICON (ICLR) at 1.68 looks cheap against book in the lower P/B ratio quartile, while Johnson & Johnson (JNJ) at 8.16 carries a premium in the upper quartile — a clear price-to-book gap.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.68
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- ICLR
- 1.68
- Min
- -5.59
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 13.53
- JNJ
- 8.16
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ICLR | JNJ |
|---|---|---|
| P/E Ratio (TTM) | 81.90 | 41.92 |
| P/S Ratio (TTM) | 1.86 | 6.69 |
| P/B Ratio (MRQ) | 1.68 | 8.16 |
| Free Cash Flow Yield (TTM) | 3.51% | 2.78% |